Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies

Stella Aslibekyan, Robert J. Straka, Marguerite R. Irvin, Steven A. Claas, Donna K. Arnett

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


High levels of HDL cholesterol (HDL-C) have traditionally been linked to lower incidence of cardiovascular disease, prompting the search for effective and safe HDL-C raising pharmaceutical agents. Although drugs such as niacin and fibrates represent established therapeutic approaches, HDL-C response to such therapies is variable and heritable, suggesting a role for pharmacogenomic determinants. Multiple genetic polymorphisms, located primarily in genes encoding lipoproteins, cholesteryl ester transfer protein, transporters and CYP450 proteins have been shown to associate with HDL-C drug response in vitro and in epidemiologic studies. However, few of the pharmacogenomic findings have been independently validated, precluding the development of clinical tools that can be used to predict HDL-C response and leaving the goal of personalized medicine to future efforts.

Original languageEnglish
Pages (from-to)355-364
Number of pages10
JournalExpert Review of Cardiovascular Therapy
Issue number3
StatePublished - Mar 2013


  • HDL
  • dyslipidemia
  • fibrates
  • niacin
  • pharmacogenomics
  • statins

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies'. Together they form a unique fingerprint.

Cite this